Source: European Parliament
Question for written answer E-001420/2025
to the Commission
Rule 144
Romana Jerković (S&D), Majdouline Sbai (Verts/ALE), Maria Grapini (S&D), Vytenis Povilas Andriukaitis (S&D), Elisabeth Grossmann (S&D), Diana Iovanovici Şoşoacă (NI), Olivier Chastel (Renew), Tilly Metz (Verts/ALE), Estelle Ceulemans (S&D), Marko Vešligaj (S&D)
Hyperemesis gravidarum (HG) is an extreme form of morning sickness and a debilitating pregnancy disease. This life-threatening condition is characterised by relentless nausea, often lasting throughout the pregnancy, uncontrollable vomiting, and frequent, serious complications. Each year, millions of women around the world experience trauma, financial strain, debility and/or incredible misery as a consequence of HG. As a result of poor patient experience and a lack of adequate treatment, there have been cases of pregnancy termination and suicide. Despite HG’s devastating impact, research on the disease remains scarce, and there is currently no effective treatment available.
- 1.Will the Commission recognise HG as an unmet medical need and allocate funding to accelerate the development of innovative treatments that millions of women desperately need?
- 2.Will the Commission develop a much-needed dedicated women’s health strategy that would address knowledge and research gaps in women’s health, including HG?
Submitted: 8.4.2025